MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 530539 | Name: ML-141
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

ML-141, also known as CID2950007, is a Cdc42 inhibitor (EC50 = 2.1 µM).

Chemical Structure

ML-141
ML-141
CAS#71203-35-5

Theoretical Analysis

MedKoo Cat#: 530539

Name: ML-141

CAS#: 71203-35-5

Chemical Formula: C22H21N3O3S

Exact Mass: 407.1304

Molecular Weight: 407.49

Elemental Analysis: C, 64.85; H, 5.19; N, 10.31; O, 11.78; S, 7.87

Price and Availability

Size Price Availability Quantity
100mg USD 450.00 2 Weeks
200mg USD 750.00 2 Weeks
500mg USD 1,450.00 2 Weeks
1g USD 2,450.00 2 Weeks
2g USD 3,850.00 2 Weeks
5g USD 5,750.00 2 Weeks
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
ML-141; ML 141; ML141; CID2950007; CID-2950007; CID 2950007.
IUPAC/Chemical Name
4-[4,5-dihydro-5-(4-methoxyphenyl)-3-phenyl-1H-pyrazol-1-yl]-benzenesulfonamide
InChi Key
QBNZBMVRFYREHK-UHFFFAOYSA-N
InChi Code
InChI=1S/C22H21N3O3S/c1-28-19-11-7-17(8-12-19)22-15-21(16-5-3-2-4-6-16)24-25(22)18-9-13-20(14-10-18)29(23,26)27/h2-14,22H,15H2,1H3,(H2,23,26,27)
SMILES Code
O=S(C1=CC=C(N2N=C(C3=CC=CC=C3)CC2C4=CC=C(OC)C=C4)C=C1)(N)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
ML141 (CID-2950007) is a potent, allosteric, selective and reversible non-competitive inhibitor of Cdc42 GTPase.
In vitro activity:
This study reports here the characterization of a Cdc42-selective guanine nucleotide binding lead inhibitor (CID-2950007) that was identified by high throughput screening. Biochemical characterization showed that the compounds act as noncompetitive allosteric inhibitors. When tested in cellular assays, the lead compound inhibited Cdc42-related filopodia formation and cell migration. The lead compound was also used to clarify the involvement of Cdc42 in the Sin Nombre virus internalization and the signaling pathway of integrin VLA-4. Reference: J Biol Chem. 2013 Mar 22;288(12):8531-8543. https://pubmed.ncbi.nlm.nih.gov/23382385/
In vivo activity:
After 24 h, ML141-injected mice spent less time than saline-injected controls in the anxiogenic center of an open field, preferring its periphery (Fig. 6C and D, n = 7, Student's t-test: P < 0.01 in all cases). Parallel suppression of the conserved brain CDC42 activity by intracerebroventricular ML141 injection caused acute anxiety in mice. Reference: Hum Mol Genet. 2014 Sep 1;23(17):4569-80. https://pubmed.ncbi.nlm.nih.gov/24722204/
Solvent mg/mL mM comments
Solubility
DMF 30.0 73.62
DMF:PBS (pH 7.2) (1:4) 0.2 0.49
DMSO 38.6 94.69
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 407.49 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Chen HY, Yang YM, Stevens BM, Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med. 2013 May;5(5):723-36. doi: 10.1002/emmm.201202140. Epub 2013 Apr 22. PMID: 23606532; PMCID: PMC3662315. 2. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Nöth J, Romero E, Swanson S, Waller A, Strouse JJ, Carter M, Chigaev A, Ursu O, Oprea T, Hjelle B, Golden JE, Aubé J, Hudson LG, Buranda T, Sklar LA, Wandinger-Ness A. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013 Mar 22;288(12):8531-8543. doi: 10.1074/jbc.M112.435941. Epub 2013 Feb 4. Erratum in: J Biol Chem. 2014 Mar 7;289(10):6837. PMID: 23382385; PMCID: PMC3605667. 3. Du H, Zhou H, Sun Y, Zhai X, Chen Z, Wang Y, Xu Z. The Rho GTPase Cell Division Cycle 42 Regulates Stereocilia Development in Cochlear Hair Cells. Front Cell Dev Biol. 2021 Oct 22;9:765559. doi: 10.3389/fcell.2021.765559. PMID: 34746154; PMCID: PMC8570139. 4. Hanin G, Shenhar-Tsarfaty S, Yayon N, Yau YH, Bennett ER, Sklan EH, Rao DC, Rankinen T, Bouchard C, Geifman-Shochat S, Shifman S, Greenberg DS, Soreq H. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23(17):4569-80. doi: 10.1093/hmg/ddu170. Epub 2014 Apr 9. Erratum in: Hum Mol Genet. 2014 Dec 15;23(24):6694. Hoe, Yau Yin [corrected to Yau, Yin Hoe]. PMID: 24722204; PMCID: PMC4119407.
In vitro protocol:
1. Chen HY, Yang YM, Stevens BM, Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med. 2013 May;5(5):723-36. doi: 10.1002/emmm.201202140. Epub 2013 Apr 22. PMID: 23606532; PMCID: PMC3662315. 2. Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, Nöth J, Romero E, Swanson S, Waller A, Strouse JJ, Carter M, Chigaev A, Ursu O, Oprea T, Hjelle B, Golden JE, Aubé J, Hudson LG, Buranda T, Sklar LA, Wandinger-Ness A. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe. J Biol Chem. 2013 Mar 22;288(12):8531-8543. doi: 10.1074/jbc.M112.435941. Epub 2013 Feb 4. Erratum in: J Biol Chem. 2014 Mar 7;289(10):6837. PMID: 23382385; PMCID: PMC3605667.
In vivo protocol:
1. Du H, Zhou H, Sun Y, Zhai X, Chen Z, Wang Y, Xu Z. The Rho GTPase Cell Division Cycle 42 Regulates Stereocilia Development in Cochlear Hair Cells. Front Cell Dev Biol. 2021 Oct 22;9:765559. doi: 10.3389/fcell.2021.765559. PMID: 34746154; PMCID: PMC8570139. 2. Hanin G, Shenhar-Tsarfaty S, Yayon N, Yau YH, Bennett ER, Sklan EH, Rao DC, Rankinen T, Bouchard C, Geifman-Shochat S, Shifman S, Greenberg DS, Soreq H. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23(17):4569-80. doi: 10.1093/hmg/ddu170. Epub 2014 Apr 9. Erratum in: Hum Mol Genet. 2014 Dec 15;23(24):6694. Hoe, Yau Yin [corrected to Yau, Yin Hoe]. PMID: 24722204; PMCID: PMC4119407.
1: Shen J, Wang R, He Z, Huang H, He X, Zhou J, Yan Y, Shen S, Shao X, Shen X, Weng C, Lin W, Chen J. NMDA receptors participate in the progression of diabetic kidney disease by decreasing Cdc42-GTP activation in podocytes. J Pathol. 2016 Oct;240(2):149-60. doi: 10.1002/path.4764. PubMed PMID: 27338016. 2: Zhan Y, Liang X, Li L, Wang B, Ding F, Li Y, Wang X, Zhan Q, Liu Z. MicroRNA-548j functions as a metastasis promoter in human breast cancer by targeting Tensin1. Mol Oncol. 2016 Jun;10(6):838-49. doi: 10.1016/j.molonc.2016.02.002. PubMed PMID: 26949125. 3: Oprea TI, Sklar LA, Agola JO, Guo Y, Silberberg M, Roxby J, Vestling A, Romero E, Surviladze Z, Murray-Krezan C, Waller A, Ursu O, Hudson LG, Wandinger-Ness A. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases. PLoS One. 2015 Nov 11;10(11):e0142182. doi: 10.1371/journal.pone.0142182. PubMed PMID: 26558612; PubMed Central PMCID: PMC4641600. 4: Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, Murray-Krezan C, Prekeris R, Sklar LA, Hudson LG, Wandinger-Ness A. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015 Oct;14(10):2215-27. doi: 10.1158/1535-7163.MCT-15-0419. PubMed PMID: 26206334; PubMed Central PMCID: PMC4596774. 5: Cheng SL, Ramachandran B, Behrmann A, Shao JS, Mead M, Smith C, Krchma K, Bello Arredondo Y, Kovacs A, Kapoor K, Brill LM, Perera R, Williams BO, Towler DA. Vascular smooth muscle LRP6 limits arteriosclerotic calcification in diabetic LDLR-/- mice by restraining noncanonical Wnt signals. Circ Res. 2015 Jul 3;117(2):142-56. doi: 10.1161/CIRCRESAHA.117.306712. PubMed PMID: 26034040; PubMed Central PMCID: PMC4490945. 6: Ferru-Clément R, Fresquet F, Norez C, Métayé T, Becq F, Kitzis A, Thoreau V. Involvement of the Cdc42 pathway in CFTR post-translational turnover and in its plasma membrane stability in airway epithelial cells. PLoS One. 2015 Mar 13;10(3):e0118943. doi: 10.1371/journal.pone.0118943. PubMed PMID: 25768293; PubMed Central PMCID: PMC4359135. 7: Zhang Y, Liu J, Luan G, Wang X. Inhibition of the small GTPase Cdc42 in regulation of epileptic-seizure in rats. Neuroscience. 2015 Mar 19;289:381-91. doi: 10.1016/j.neuroscience.2014.12.059. PubMed PMID: 25595978. 8: Hsu CR, Pan YJ, Liu JY, Chen CT, Lin TL, Wang JT. Klebsiella pneumoniae translocates across the intestinal epithelium via Rho GTPase- and phosphatidylinositol 3-kinase/Akt-dependent cell invasion. Infect Immun. 2015 Feb;83(2):769-79. doi: 10.1128/IAI.02345-14. PubMed PMID: 25452552; PubMed Central PMCID: PMC4294243. 9: Kumar A, Al-Sammarraie N, DiPette DJ, Singh US. Metformin impairs Rho GTPase signaling to induce apoptosis in neuroblastoma cells and inhibits growth of tumors in the xenograft mouse model of neuroblastoma. Oncotarget. 2014 Nov 30;5(22):11709-22. PubMed PMID: 25365944; PubMed Central PMCID: PMC4294363. 10: Antolín AA, Mestres J. Distant polypharmacology among MLP chemical probes. ACS Chem Biol. 2015 Feb 20;10(2):395-400. doi: 10.1021/cb500393m. PubMed PMID: 25365788. 11: Chen C, Song X, Ma S, Wang X, Xu J, Zhang H, Wu Q, Zhao K, Cao J, Qiao J, Sun X, Li D, Zeng L, Li Z, Xu K. Cdc42 inhibitor ML141 enhances G-CSF-induced hematopoietic stem and progenitor cell mobilization. Int J Hematol. 2015 Jan;101(1):5-12. doi: 10.1007/s12185-014-1690-z. PubMed PMID: 25315193. 12: Weinberg MS, Nicolson S, Bhatt AP, McLendon M, Li C, Samulski RJ. Recombinant adeno-associated virus utilizes cell-specific infectious entry mechanisms. J Virol. 2014 Nov;88(21):12472-84. doi: 10.1128/JVI.01971-14. PubMed PMID: 25142580; PubMed Central PMCID: PMC4248914. 13: Hanin G, Shenhar-Tsarfaty S, Yayon N, Yau YH, Bennett ER, Sklan EH, Rao DC, Rankinen T, Bouchard C, Geifman-Shochat S, Shifman S, Greenberg DS, Soreq H. Competing targets of microRNA-608 affect anxiety and hypertension. Hum Mol Genet. 2014 Sep 1;23(17):4569-80. doi: 10.1093/hmg/ddu170. Erratum in: Hum Mol Genet. 2014 Dec 15;23(24):6694. Hoe, Yau Yin [corrected to Yau, Yin Hoe]. PubMed PMID: 24722204; PubMed Central PMCID: PMC4119407. 14: McNary SM, Athanasiou KA, Reddi AH. Transforming growth factor β-induced superficial zone protein accumulation in the surface zone of articular cartilage is dependent on the cytoskeleton. Tissue Eng Part A. 2014 Mar;20(5-6):921-9. doi: 10.1089/ten.TEA.2013.0043. PubMed PMID: 24116978; PubMed Central PMCID: PMC3938930. 15: Chen HY, Yang YM, Stevens BM, Noble M. Inhibition of redox/Fyn/c-Cbl pathway function by Cdc42 controls tumour initiation capacity and tamoxifen sensitivity in basal-like breast cancer cells. EMBO Mol Med. 2013 May;5(5):723-36. doi: 10.1002/emmm.201202140. PubMed PMID: 23606532; PubMed Central PMCID: PMC3662315. 16: Surviladze Z, Waller A, Strouse JJ, Bologa C, Ursu O, Salas V, Parkinson JF, Phillips GK, Romero E, Wandinger-Ness A, Sklar LA, Schroeder C, Simpson D, Nöth J, Wang J, Golden J, Aubé J. A Potent and Selective Inhibitor of Cdc42 GTPase. 2010 Feb 27 [updated 2010 Dec 16]. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-. Available from http://www.ncbi.nlm.nih.gov/books/NBK51965/ PubMed PMID: 21433396.